Welcome to our dedicated page for Innate Pharma Sa news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma Sa stock.
Innate Pharma S.A. (Symbol: IPHA) is a clinical-stage biotechnology company at the forefront of cancer treatment innovation. Specializing in immuno-oncology, Innate Pharma develops first-in-class therapeutic antibodies designed to harness the innate immune system. This pioneering approach helps the body's natural defenses recognize and combat cancer cells more effectively.
The company's diverse pipeline includes four clinical-stage antibodies along with several preclinical candidates. Key products under development include lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401, and IPH6501. These therapies aim to address a wide range of cancer types, particularly those with high unmet medical needs.
Innate Pharma has made significant strides in the discovery and development of checkpoint inhibitors, leveraging its deep understanding of natural killer cell biology. This expertise has led to strategic partnerships with renowned biopharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi.
The company’s revenue streams primarily come from research collaborations, licensing agreements, and milestone payments from its pharmaceutical partners. Innate Pharma's proprietary platform, ANKET (Antibody-based NK cell Engager Therapeutics), forms the backbone of its innovative therapeutic strategies.
With a commitment to advancing cancer treatment, Innate Pharma continues to make significant progress in clinical trials and research, aiming to bring transformative therapies to patients worldwide.
Innate Pharma has announced the filing of a prospectus supplement with the SEC for a new At-The-Market (“ATM”) program, allowing for the offering of up to
Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) announced its participation in the Van Lanschot Kempen Life Sciences Conference 2023 on April 25-26 in
Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) reported its total number of shares outstanding and voting rights as of April 1, 2023. The company has a total of 80,222,007 ordinary shares and 6,514 and 7,581 preferred shares from 2016 and 2017, respectively. The total number of theoretical voting rights stands at 80,979,847, with 80,961,272 exercisable voting rights. These figures comply with the French 'Code de Commerce' and AMF regulations. As a clinical-stage biotechnology firm, Innate focuses on developing immunotherapies for cancer using its proprietary ANKET® platform, partnering with major firms like Sanofi and AstraZeneca to enhance its R&D efforts.
Innate Pharma will hold its Annual General Meeting (AGM) on May 12, 2023, at 10:30 a.m. CEST in Marseille, France. The meeting will be broadcast live, providing shareholders access to discuss the agenda and proposed resolutions.
Shareholders must register their shares at least two business days before the AGM. Those holding bearer shares need to secure a 'certificate of shareholding' from their brokers. Written questions must be submitted by email at least two business days prior to the meeting.
The company is actively developing immunotherapies for cancer patients through its innovative ANKET® platform and collaborations with partners like Sanofi and AstraZeneca.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) has filed its 2022 Universal Registration Document with the AMF and its annual report on Form 20-F with the SEC for the year ending
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) announced an exclusive license agreement with Takeda for developing antibody drug conjugates (ADC) targeting an undisclosed area, focusing on Celiac disease. Takeda will manage the development, manufacturing, and commercialization of products. Innate will receive a $5 million upfront payment and could earn up to $410 million in future milestone payments, plus royalties on net sales. This collaboration aims to leverage Innate's antibody engineering expertise, expanding its scientific applications beyond oncology.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) expanded its collaboration with Sanofi on NK cell engager therapeutics, receiving a €25 million upfront payment. The company also reported encouraging preliminary efficacy data for lacutamab in advanced cutaneous T cell lymphoma, with a global objective response rate (ORR) of 28.6%. Additionally, the first patient was dosed in the Phase 3 PACIFIC-9 trial for lung cancer, triggering a $50 million milestone payment from AstraZeneca. As of December 31, 2022, Innate's cash position was €136.6 million, supporting operations into mid-2025. The company aims for key clinical milestones in 2023.
On March 1, 2023, Innate Pharma SA announced its total number of shares outstanding and voting rights as required by French regulations. The company has 80,218,457 ordinary shares and 6,514 Preferred Shares from 2016 and 7,581 from 2017. The total number of theoretical voting rights stands at 80,976,297, with exercisable voting rights at 80,957,722. Innate Pharma focuses on oncology, striving to improve patient outcomes through therapeutic antibodies. The company has established significant partnerships with major biopharmaceutical firms.
FAQ
What is the current stock price of Innate Pharma Sa (IPHA)?
What is the market cap of Innate Pharma Sa (IPHA)?
What does Innate Pharma S.A. specialize in?
What are some of Innate Pharma's key products?
How does Innate Pharma generate revenue?
Who are some of Innate Pharma's notable partners?
What is ANKET?
What is the focus of Innate Pharma’s current projects?
What stage is Innate Pharma in?
What makes Innate Pharma's approach unique?
What is immuno-oncology?
How does Innate Pharma contribute to cancer research?
